Skip to main content
OpenTrials

Clinical trial condition

Recurrence

Explore clinical trials studying Recurrence. Study availability and eligibility vary by location and protocol.

2,312 public trials 521 recruiting studies
Refine in advanced search Browse all conditions

Recurrence trial results

Completed

REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy

NCT05621148

Conditions
Bruton Tyrosine Kinase Inhibitor, CLL, Refractory, CLL, Relapsed, +5 more
Locations
  • CHU Estaing - Hématologie Clinique Adulte Clermont-Ferrand, France
  • Centre Léon Bérard - Hématologie Lyon, France
  • Institut Paoli-Calmettes - Hématologie Clinique Marseille, France
  • MONTPELLIER - Hôpital Saint-Eloi - Hématologie Clinique Montpellier, France
View Trial Details
Completed

A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial (PCD)

NCT02244125

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • CHRU Hopital Sud Amiens, France
  • Centre Hospitalier de la côte Basque Bayonne, France
  • Hôpital Avicenne Bobigny, France
  • ICH - Hôpital A. Morvan Brest, France
View all 30 locations
View Trial Details
Completed

Real-life Efficacy and Toxicity of Brentuximab-Vedotin Associated With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL-R2-B2)

NCT07145125

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Hodgkin Disease, +11 more
Locations
  • CH de la Côte Basque, service Hématologie Clinique Bayonne, France
  • CHU de Bordeaux, service Hématologie Clinique et Thérapie cellulaire Bordeaux, France
  • CHU de Caen, service Hématologie Clinique Caen, France
  • Institut Paoli Calmettes, service Hématologie Clinique Marseille, France
View Trial Details
Completed

Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts

NCT03160079

Conditions
B-Cell Acute Lymphoblastic Leukemia, Adult, Burkitt Lymphoma, DNA Virus Infections, +19 more
Locations
  • UCSF Fresno Community Cancer Institute Clovis, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • UC Irvine Health Chao Family Comprehensive Cancer Center Orange, California, United States
  • UCSF Comprehensive Cancer Center San Francisco, California, United States
View Trial Details
Completed

Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)

NCT04220866

Conditions
Carcinoma, Carcinoma, Squamous Cell, Disease Attributes, +13 more
Locations
  • UCLA Hematology & Oncology ( Site 0005) Los Angeles, California, United States
  • University of California at San Francisco ( Site 0006) San Francisco, California, United States
  • Henry Ford Hospital ( Site 0012) Detroit, Michigan, United States
  • Washington University ( Site 0021) St Louis, Missouri, United States
View all 34 locations
View Trial Details
Completed

Study of Diagnostic Performance of [18F]CTT1057 in BCR

NCT04838613

Conditions
Disease Attributes, Genital Diseases, Genital Diseases, Male, +12 more
Locations
  • Explorer Molecular Imaging center Sacramento, California, United States
  • Novartis Investigative Site Marseille, France
  • Novartis Investigative Site Marseille, France
  • Novartis Investigative Site Nîmes, France
View all 13 locations
View Trial Details

Related conditions